NCT01494662: HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

NCT01494662
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Chemotherapy, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients with leptomeningeal metastases as the only site of CNS disease
https://ClinicalTrials.gov/show/NCT01494662

Comments are closed.

Up ↑